Synthetic Peptide Hormones, PHI PHI has recently been isolated from porcine duodenum as a new peptide factor with VIP-like activities. Its primary structure corresponds to a linear heptacosapeptide amide characterized by a remarkable sequence homology to the other known members of the glucagon family. The synthesis of this hormone candidate has been performed applying the strategy of overall acid-labile side-chain protection and the fragment condensation procedure. Upon assembly of the fragments to the fully protected heptacosapeptide amide, acidolytic deprotection with trifluoroacetic acid followed by purification of the resulting crude product via ion exchange chromatography and partition chromatography yielded synthetic PHI at a high degree of purity as judged from different analytical tests. Comparative analyses of the synthetic and natural product by means of chromatographic and biological assays confirmed the identity of the two PHI preparations.
A new hormone candidate designated with the acronym PHI -the peptide factor having as Nterminal residue histidine and as C-terminal isoleucine amide -was isolated by Tatemoto and Mutt from porcine upper intestinal tissue [1, 2] , Its primary structure has recently been elucidated as a linear heptacosapeptide amide with the following amino acid sequence [3 ] :
H-His-Ala-Asp-Gly-Val-Phe-Thr-SerAsp-Phe-Ser-Arg-Leu-Leu-Gly-Gln-LeuSer-Ala-Lys-Lys-Tyr-Leu-Glu-Ser-LeuIle-NHo PHI possesses a remarkable sequence homology to other known members of the glucagon family, particularly to secretin and VIP as shown in Fig. 1 . and exhibits VIP-like activities. For the total svn-* Reprint requests to Prof. Dr. E. Wünsch. 0340-5087/82/0600-0772/S 01.00/0 thesis of this new peptide factor we have applied the strategy successfully used in our previous total syntheses of glucagon [4] , secretin [5J, GlP-[l-38] [6] and Nie 17 -VIP [7] , i.e. i) the maximum side-chain protection with acid labile groups on £er£-butanol and 1-adamantol basis in combination with the benzyloxycarbonyl and the 2-nitrophenylsulfenyl derivatives for the a-amino protection in the intermediate chain-elongation steps;
ii) the fragment condensation procedure based on the preparation of suitably protected segments, in the present case corresponding to sequences 1-6, 7-11, 12-14, 15-18, 19-23 and 24-27, respectively, followed by their condensation in sequence order starting from the C-terminal end, to the fully protected heptacosapeptide amide;
iii) the final acidolytic deprotection followed by purification of the resulting crude material via chromatographic methods.
Synthesis of the Fragments of PIII

Fragment I (sequence 24-27):
The protected tetrapeptide amide Z-Glu(OBu ? )-Ser(Bu')-Leu-Ile-NH2 [24-27 a] corresponding to the C-terminal sequence 24-27 was prepared according to Scheme Alternatively the acylation steps have also been performed using the condensation agent X-(2-iso-* The amino acid derivatives used in this synthesis were prepared according to known procedures [8] .
cyanoethyl)-morpholine/X-hydroxysuccinimide, recently proposed by Aigner and Marquarding [9] . The peptide derivatives [26-27aJ, [25-27aJ and [24-27 a] were obtained in yields and analytically purity equivalent to those of the X-hydroxysuccinimido ester procedure.
Fragment II (sequence 19-23):
For the synthesis of the carboxyl-free fragments described herein we made use of the method of Anderson et al. [10] , i.e. acylation of amino acids and peptides or peptide derivatives with active esters in aqueous-organic or organic media on addition of one equivalent of base, only in the dipeptide steps. Subsequent acylations, mainly via X-hydroxysuccinimido esters, were performed on the amino-and carboxyl-free peptide derivatives in dimethylformamide (in solution or suspension) without any addition of bases such as tertiary amines. This new simple condensation procedure allows a fast and mild workup; additionally the danger of razemization due to overdosage of bases is avoided. Consequently the tetrapeptide derivative H-Lys( H -His -Ser -Asp -Ala -Val -Phe -Thr -Asp -Asn -Tyr -Thr -Arg -Leu -ArgGlucagon: H -His -Ser -Gin -Glv -Thr -Phe -Thr -Ser -Asp -Tyr -Ser -Lys -Tyr -Lou-GIP:
H -Tvr -Ala -Glu -Gly -Thr -Phe -lie -Ser -Asp -Tyr -Ser -He -Ala -Met-PHI:
H -His -Ala -Asp -Gly -Val -Phe -Thr -Ser -Asp -Phe -Ser -Arg -Lou - Leu-15  16  17  18  19  20  21  22  23  24  25  26  27  28  29 30 Asp -Ser -Ala -Arg -Leu -Gin -Arg -Leu -Leu -Gin -Gly -Leu -Val -NHo Lys -Gin -Met -Ala -Val -Lys -Lys -Tyr -Leu -Asn -Ser -lie -Leu -Asn -NHo Asp -Ser -Arg -Arg -Ala -Gin -Asp -Phe -Val -Gin -Trp -Leu -Met -Asn -Thr -OH Asp -Lys -lie -Arg -Gin -Gin -Asp -Phe -Val -Asn -Trp -Leu -Leu -Ala -. . . Gly -Gin -Leu -Ser -Ala -Lys -Lys -Tyr -Leu -Glu -Ser -Leu -lie -NH2 
Fragment III (sequence 15-18):
H-Ser(Bu*)-OMe [18] was reacted with Z-LeuOXSu [17] to yield the dipeptide derivative [17-18 a] which, in turn, upon saponification to [17-18 b] was N'-deprotected by catalytic hydrogenolysis according to our previously described procedures [11] . The resulting dipeptide derivative H-LeuSer(Bu*)-OH [17-18c] was elongated at the X-terminus by successive acylation steps via active esters, i.e, using Z-Gln-OXp [16] and Xps-GlyOXSu [15] , respectively, with intermediate X^-debenzyloxycarbonylation of the tetrapeptide derivative [16-18a] (Scheme III) . Fragment III, XpsGly-Gln-Leu-Ser(Bu')-0H [15] [16] [17] [18] 
Fragment IV (sequence 12-14):
The dipeptide H-Leu-Leu-OH [13] [14] prepared according to known procedures [12] was reacted with Z-Arg(Z2)-ONSu [12] to produce fragment IV, Z-Arg(Z2)-Leu-Leu-OH [12] [13] [14] [17-18a] j 1 N NaOH Z-Leu-Ser(Bu')-OH [17-18b] i H2/Pd Z-Gln-ONp [10] [12] [13] [14] Schome IV. Synthesis of fragment IV corresponding to sequence 12-14.
Fragment V (sequence 7-11):
Upon acylation of H-Ser(Bu')-OH [11] with ZPhe-OXSu [10] in dioxane/lX XaOH according to Anderson et al. [10] , the resulting [10-11 a] was X adeprotected to H-Phe-Ser(Bu')-OH [10-1 lb]; this dipepticle derivative was elongated at the X-tcrminus in stepwise manner via the active ester method as described for fragment II in absence of tertiary amines following Scheme V. Z-Thr(Bu')-Ser(Bii')-Asp(OBu')-Phe-Ser(Bu f )-OH [7] [8] [9] [10] [11] 
Fragment VI (sequence 1-6):
H-Phe-OBu* [6] was reacted with Z-Val-OXSu [5] The amine-free side-chain protected segment ] was subsequently coupled with the tripeptide Z-Arg(Z2)-Leu-Leu-OH [12] [13] [14] in X^-methylpyrrolidone/dimethylacetamide using again dicyclohexylcarbodiimide/X-hydroxysuccinimide as condensation agent to yield the fully protected hexadecapeptide [12-27a] . This peptide derivative was Upon neutralizing [12-27 b] x HBr with equivalent amounts of triethylamine the amine-free hexadecapeptide derivative was assembled with fragment V, ?.e.Z-Thr(Bu f )-Ser(Bu f )-Asp(OBu f )-Phe-Sei'(Bu t )-OH [7] [8] [9] [10] [11] in X-methylpyrrolidone/dimethylformamide/dimethylacetamide via dicyclohexylcarbodiimide/l-hydroxybenzotriazole [16] to Z-Thr(Bu')-Ser(BuO-Asp(()BuO-Phe-Ser(Bu')-Arg(HBr)-LeuLeu-Gly-Gln-Leu-Ser(Bu ( )-Ala-Lys(Adoc)-Lys-(Adoc)-Tyr(Bu')-Leu-Glu(OBu')-Ser(Bu ( )-Leulle-XHo [7-27a] in 93% yield. Subsequent catalytic hydrogenolysis in 90% aqueous trifluoroethanol in the presence of palladium on charcoal produced the corresponding X a -deprotected eneicosapeptide amide [7-27b] [1-27a] in high yields: on tic (chloroform/ 80% acetic acid/trifluoroethanol. 4:0.5:0.6; chloroform/80% acetic acid/methanol, 6:1:1) two small impurities were detected of which one corresponds to unreacted amino component [7-27b] . The contaminants could not be eliminated by simple purification procedures; thus the resulting product was submitted without further purifications to the following deprotection step. The crude product (PHI-A) was chromatographied on the ion exchange resin CM-Bio-Gel A with 0.02M ammonium acetate buffer (pH 4.8) as eluent to remove most of the impurities with lower .Rf-values on hplc. The final purification of the resulting main fraction PHI-Bi was achieved by partition chromatography on Sephadex G-25F using the upper-phase of the solvent system %-butanol/ 0.01 N HCl followed by its lower phase as eluent. (PHI-Ci) was repeatedly ultrafiltered (millipore, type GS 0.22 /um) and lyophilized; the synthetic PHI [1-27 b] was obtained in 25-30% yield based on the last analytically characterized intermediate [7-27 b] . Both the tic (Fig. 2 ) and the hplc (Fig. 3) Chromatographic comparison of the synthetic and natural PHI as well as of their tryptic digests by hplc (Figs. 4-5 ) and the biological assay based on the binding potency of synthetic and natural PHI to VIP-receptors present in the rat liver plasma membranes [20] (Fig. 6 ) confirm the identity of the two PHI preparations.
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* The percentage of n-amino acids corresponds to the values expected from the hydrolysis-dependent racemization as determined by Frank et al. [19] ,
